Santhera Pharmaceuticals Holding AG (SANN.SW)

Santhera Pharmaceuticals Holding AG (SANN.SW) — VMCI valuation read

Santhera Pharmaceuticals Holding AG (SANN.SW) carries a VMCI composite of 30/100, 20 points below the Healthcare sector median of 50. Among mid-cap names, that gap places SANN.SW in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The SANN.SW insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads SANN.SW trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 3.3x is the binding constraint on the bear case, the line to track on Santhera Pharmaceuticals Holding AG's next 10-Q.

SANN.SW fell 2.8% over the trailing 7 days, with a -15.7% read on a 30-day basis.